BTCC / BTCC Square / Global Cryptocurrency /
Merck Stock Dips on Mixed Q2 Results Amid Strategic Shift

Merck Stock Dips on Mixed Q2 Results Amid Strategic Shift

Global Cryptocurrency
Release Time:
2025-07-30 03:04:01
0
BTCCSquare news:

Merck & Co. shares fell nearly 2% Tuesday, underperforming pharmaceutical peers after reporting a 2% year-over-year revenue decline to $15.8 billion. While cancer drug Keytruda saw 9% sales growth and animal health revenue ROSE 11%, GAAP net income dropped 8% to $5.4 billion.

The results missed revenue estimates but beat adjusted EPS forecasts, prompting CEO Robert Davis to announce a "multi-year optimization initiative" redirecting resources from mature business segments to emerging growth drivers. Market reaction reflects investor skepticism about Merck's transitional phase as it rebalances its portfolio.

Articles on this site are sourced from public networks or curated by AI for informational purposes only and do not represent BTCC’s views. Original rights belong to the respective authors. For copyright concerns, please contact [email protected]. BTCC assumes no liability for the accuracy, timeliness, or completeness of this information, and disclaims all liability arising from reliance on such content. This content is for reference only and should not be taken as investment, legal, or commercial advice.

|Square

Get the BTCC app to start your crypto journey

Get started today Scan to join our 100M+ users